
Sign up to save your podcasts
Or
On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).
5
77 ratings
On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).
38,152 Listeners
27,321 Listeners
30,959 Listeners
22,088 Listeners
43,491 Listeners
3,452 Listeners
2,608 Listeners
9,374 Listeners
8,216 Listeners
57,800 Listeners
4,357 Listeners
2,044 Listeners
9,559 Listeners
14 Listeners
5,104 Listeners